A trial date has yet to be set for a patent infringement suit filed by Shire plc against Watson Laboratories, Inc. relating to ADDERALL XR.
In February 2011, Shire was notified…
Shire Ltd.’s patent infringement suit against Teva remains pending.
On March 16, April 5, and April 26, 2010, Shire received Paragraph IV Notice Letters from Teva, Actavis, and Anchen Pharmaceuticals Inc.,…
Shire Ltd.’s suit against Nostrum Pharmaceuticals, Inc., relating to their ANDAs seeking approval to market generic versions of 100mg, 200mg and 300mg strengths of CARBATROL was settled on March 10,…
No trial date has been set for Shire Ltd.’s patent infringement suits against Barr, Mylan, Inc., Mylan Pharmaceuticals, Inc., and Matrix Laboratories, Inc., and Natco Pharma Limited.
In February 2009, Shire…
Generics UK Ltd.’s appeal regarding the ruling in its rectification action against Shire Ltd. remains pending.
Generics UK seeks a declaration that the duration of the Supplementary Protection Certificate for European…
Shire Ltd. is defending itself against Mt. Sinai School of Medicine of New York University’s patent infringement lawsuits in Sweden and Germany.
On April 14, 2010, Mt. Sinai sought to initiate…
A hearing date has yet to be set on Actavis Elizabeth LLC’s appeal regarding the U.S. District Court for the District of Columbia’s ruling on VYVANSE, according to Shire Ltd.’s…
No trial date has been set for Shire Ltd.’s suit against Teva Pharmaceuticals Industries Ltd. for the alleged infringement of U.S. Patent Nos. 5,912,013 and 5,326,570.
Both patents relate to carbamazepine.
The…
Generics UK Ltd.’s appeal to the ruling in its rectification action against Shire Ltd. will be heard in October 2009.
Generics UK seeks a declaration that the duration of the Supplementary…
Sandoz Inc.’s appeal relating to the patent infringement case, Shire v Impax, remains pending, according to Shire Ltd.’s latest Quarterly Report filed with the U.S. Securities and Exchange Commission.
The U.S.…